Guardant Health Inc
Closed
SectorHealthcare
131.38 1.01
Overview
Share price change
24h
Min
128
Max
133.21
Income | 16M -112M |
|---|---|
Sales | 20M 302M |
EPS | -0.45 |
Profit margin | -37.152 |
Employees | 2,490 |
EBITDA | 18M -101M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +9.54% upside |
Next Earnings | 29 Jul 2026 |
|---|
Market Cap | 4.6B 17B |
|---|---|
Previous open | 130.37 |
Previous close | 131.38 |
Guardant Health Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Guardant Health Inc Forecast
Price Target
By TipRanks
9.54% upside
12 Months Forecast
Average 143.39 USD 9.54%
High 185 USD
Low 120 USD
Based on 20 Wall Street analysts offering 12 month price targets forGuardant Health Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
